1 / 22

Anoro Ellipta ™ - umeclidinium/vilanterol

Anoro Ellipta ™ - umeclidinium/vilanterol. Manufacturer: GlaxoSmithKline FDA Approval Date: 12/18/2013. Anoro Ellipta ™ - Umeclidinium/Vilanterol Clinical Application. Indications: Maintenance treatment of airflow obstruction in patients with COPD Place in therapy:

laban
Télécharger la présentation

Anoro Ellipta ™ - umeclidinium/vilanterol

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anoro Ellipta™ - umeclidinium/vilanterol Manufacturer: GlaxoSmithKline FDA Approval Date: 12/18/2013

  2. Anoro Ellipta™ - Umeclidinium/VilanterolClinical Application • Indications: • Maintenance treatment of airflow obstruction in patients with COPD • Place in therapy: • Anoro Ellipta is the first fixed-dose combination of a LABA and anticholinergic agent

  3. Anoro Ellipta™ - Umeclidinium/VilanterolClinical Application • Contraindications: • Severe hypersensitivity to milk protein or any ingredients • Black Box warnings • LABAs increase the risk of asthma-related death

  4. Anoro Ellipta™ - Umeclidinium/VilanterolClinical Application • Warnings and Precautions • Do not initiate in acutely deteriorating COPD or to treat acute symptoms • Do not use with other LABAs • Discontinue if paradoxical bronchospasm occurs • Use with caution in cardiovascular disorders, convulsive disorders, thyrotoxicosis, diabetes, ketoacidosis, and narrow-angle glaucoma • Worsening of urinary retention may occur • Monitor for hypokalemia and hyperglycemia

  5. Anoro Ellipta™ - Umeclidinium/VilanterolClinical Application • Pregnancy: • Category C • Lactation: • It is unknown if Anoro Ellipta is excreted in breast milk so use with caution

  6. Anoro Ellipta™ - Umeclidinium/VilanterolDrug Facts • Pharmacology: • Umeclidinium (anticholinergic): inhibits M3 recepto at the smooth muscle leading to bronchodilation. Also known as Long-Acting Muscarinic Antagonist (LAMA) • Vilanterol (LABA): stimulation of intracellular adenyl cyclase, which catalyzes ATP to cAMP. Increased cAMP causes relaxation of bronchial smooth muscle

  7. Anoro Ellipta™ - Umeclidinium/VilanterolDrug Facts

  8. Anoro Ellipta™ - Umeclidinium/VilanterolDrug Interactions • Drug Interactions – Object Drugs: • Non-potassium-sparing diuretic induced hypokalemia is () by vilanterol • Anticholinergic medications () anticholinergic effects of umeclidinium

  9. Anoro Ellipta™ - Umeclidinium/VilanterolDrug Interactions • Drug Interactions – Precipitant Drugs: • CYP3A4 inhibitors () levels of vilanterol • MAOI and TCAs () QTc interval when used with vilanterol • Beta blockers () effects of vilanterol

  10. Anoro Ellipta™ - Umeclidinium/VilanterolAdverse Effects

  11. Anoro Ellipta™ - Umeclidinium/VilanterolMonitoring Parameters • Efficacy Monitoring: • Improvement in lung function • Toxicity Monitoring: • Cardiac monitoring is recommended in cases of overdosages

  12. Anoro Ellipta™ - Umeclidinium/VilanterolMonitoring Parameters • Toxicity Signs/Symptoms: • Umeclidinium: anticholinergic signs and symptoms • Vilanterol: angina, hypertension or hypotension, tachycardia, arrhythmias, nervousness, headache, tremor, seizures, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, metabolic acidosis

  13. Anoro Ellipta™ - Umeclidinium/VilanterolPrescription Information • Dosing: • Uneclidinium/vilanterol 62.5 mcg/25 mcg as 1 inhalation once daily • Cost: – Not available at time of review

  14. Anoro Ellipta™ - Umeclidinium/VilanterolLiterature Review • Objective: to examine the efficacy and safety of umeclidinium/vilanterol (UME/VI) compared with UME and VI monotherapies in COPD • Treatment • UMEC/VI 62.5/25 mcg • UME 62.5 mcg • VI 25 mcg • Placebo • Primary endpoint: FEV1 on Day 169 Donohue JF, et al. Respir Med. 2013;107:1538-46

  15. Anoro Ellipta™ - Umeclidinium/VilanterolLiterature Review • Statistics • 273 patients in each active arm and 183 patients in the placebo arm would have 90% power to detect a 1-unit difference between treatments. • This also gae >99% to detect a 0.1 L difference in trough FEV1 • Assuming a withdrawal rate of 30%, 399 patients were needed for the active arms and 266 patients were needed for placebo Donohue JF, et al. Respir Med. 2013;107:1538-46

  16. Anoro Ellipta™ - Umeclidinium/VilanterolLiterature Review Patient Demographics Donohue JF, et al. Respir Med. 2013;107:1538-46

  17. Anoro Ellipta™ - Umeclidinium/VilanterolLiterature Review Primary Endpoint Donohue JF, et al. Respir Med. 2013;107:1538-46

  18. Anoro Ellipta™ - Umeclidinium/VilanterolLiterature Review Adverse Effects Donohue JF, et al. Respir Med. 2013;107:1538-46

  19. Anoro Ellipta™ - Umeclidinium/VilanterolLiterature Review • Study Conclusions • Once-daily umeclidinium/vilanterol significantly improved lung function and symptoms in patients with COPD compared to monotherapy or placebo Donohue JF, et al. Respir Med. 2013;107:1538-46

  20. Anoro Ellipta™ - Umeclidinium/VilanterolLiterature Review • Study Limitations • No head-to-head comparisons of LAMA or LABA monotherapy • No approved LAMA/LABA combination therapy for comparison • Concomitant inhaled corticosteroid or bronchodilator therapies were allowed Donohue JF, et al. Respir Med. 2013;107:1538-46

  21. Anoro Ellipta™ - Umeclidinium/VilanterolSummary • First approved combination of a long acting-anticholinergic (umeclidinium) and a LABA (vilanterol) • Indicated for the maintenance treatment of COPD. NOT approved for asthma. • It has one black box warning: LABAs increase the risk of asthma-related death • Well tolerated. Side effects include; Pharyngitis, diarrhea, and pain in the extremities

  22. Anoro Ellipta™ - Umeclidinium/VilanterolReferences • AnoroEllipta [package insert]. GlaxoSmithKline. Dec. 2013. • Donohue JF, et al. Respir Med. 2013;107:1538-46

More Related